港股8月怎么投？四大赛道ETF受机构关注

Core Viewpoint - The Hong Kong stock market has seen significant inflows and upward trends, with the Hang Seng Index and Hang Seng Tech Index both rising over 2.8% in July, driven by a combination of domestic and foreign investments [1] Group 1: Market Performance - In July, the Hong Kong Stock Connect saw an inflow of 125.2 billion RMB, an increase of over 70% compared to June, indicating a strong liquidity environment [1] - The Hang Seng Index and Hang Seng Tech Index both experienced substantial gains, with the Hang Seng Tech Index rising by 5.8% [1] Group 2: Investment Opportunities - According to Guosen Securities, Hong Kong stocks remain in a reasonable valuation range compared to A-shares, with a focus on sectors such as low-valuation internet and AI leaders, innovative pharmaceuticals, resources benefiting from "anti-involution," new consumption with strong fundamentals, and improving non-bank financial institutions [1] - Specific ETFs like the Hong Kong Stock Connect Tech ETF (159262), Innovative Pharma ETF (513120), Consumption ETF (159699), and Non-bank Financial ETF (513750) are highlighted as effective tools for investors to capture opportunities in these sectors [1] Group 3: ETF Performance - The Hong Kong Stock Connect Tech ETF (159262) has outperformed the Hang Seng Tech Index since its launch, rising over 13% compared to the index's 5.8% increase, with a TTM P/E ratio of 23.5, positioned at the 52nd percentile historically [2] - The Innovative Pharma ETF (513120) has seen a remarkable year-to-date return of over 102%, with a current size exceeding 16.5 billion RMB, making it the largest innovative pharma ETF in the market [2] - The Consumption ETF (159699) tracks the Hang Seng Consumption Index with a P/E ratio of 18.91, providing a balanced exposure to consumer trends, particularly among Generation Z [3] - The Non-bank Financial ETF (513750) has attracted significant investment, with a one-year return of 92.58% and a P/E ratio of approximately 10, indicating a strong valuation advantage [3] Group 4: Market Outlook - The combination of valuation recovery and ample liquidity in the Hong Kong market is expected to drive continued interest in technology, pharmaceuticals, new consumption, and non-bank financial sectors [4] - The ongoing "anti-involution" policies and rising global inflation expectations are likely to enhance the medium to long-term investment value of the technology and pharmaceutical sectors [4]